ClinicalTrials.gg
RecruitingNCT07251595Updated Feb 18, 2026

A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo

A Phase 2 interventional study of SHR0302 Tablets and SHR0302 Base Gel in Non-segmental Vitiligo, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Vitiligo with a site in China — 24 open to participants now, 29 under way, 8 of them phase 3. Vitiligo · China.

Planned enrollment
12th of 32
176 · median 150
Started
2025
with 10 others
Phase 2
11 of 39
8 open now
Primary completion
2027-03
later than 10 of 28 live
Registered
25th of 39
by date
Lead sponsor
2 of 39
Jiangsu HengRui Medicine Co., Ltd.

Among the 39 studies in Vitiligo with a site in China, this one is the 12th largest by planned enrollment of the 32 interventional ones that give a count, is one of 11 that started in 2025, is one of 11 in phase 2, reaches primary completion later than 10 of the 28 other live ones, and was the 25th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

24 of the 39 studies in Vitiligo with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Vitiligo with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy, and safety of SHR0302 tablets as single therapy or in combination with SHR0302 Base gel for patients with non-segmental vitiligo.

03

Conditions studied

  • Non-segmental Vitiligo

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the form before the clinical trial.
  2. On the day of signing the informed consent form, the age must be between 18 and 75 years old (inclusive), and it can be either male or female.
  3. The subjects and their partners had no intention of having children during the study period and within one month after the administration of the drug, did not donate sperm or eggs, and voluntarily adopted effective measures. The serum pregnancy test results of the female subjects must be negative and they must not be in the lactation period.
  4. During the screening process, it was clinically diagnosed as non-segmental vitiligo.
  5. Throughout the entire research process, the participants agreed to stop using all treatments related to vitiligo as well as any cosmetic products with therapeutic effects.

Exclusion criteria

Exclusion Criteria:

  1. Subjects diagnosed with segmental, mixed or undifferentiated vitiligo; or subjects previously diagnosed with other skin pigmentation disorders.
  2. When the facial skin lesions caused by vitiligo cover more than 33% of the area with white hair.
  3. During the screening period or at the baseline, there were other active skin lesions or skin infections that might interfere with the use of the study drug or the evaluation of the drug's efficacy.
  4. Subjects with a history of related infections/communicable diseases or infection/contagion history.
  5. Known or suspected history of .
  6. Tuberculosis (TB) or latent tuberculosis infection.
  7. Positive for antibody HIV-Ab, positive for syphilis-specific antibody, positive for virus antibody HCV-Ab, or virus (HBV) infection.
  8. Subjects who have malignant tumors or have a history of malignant tumors.
  9. Abnormal thyroid function, with a history of thrombotic diseases within the previous 12 months, and having experienced a cardiovascular or cerebrovascular event that required hospitalization within the previous 12 months.
  10. There are serious abnormalities in the cardiovascular, mental, renal, liver, immune, gastrointestinal, urogenital, nervous, skeletal-muscular, skin, sensory, endocrine or hematological systems.
  11. Pregnant women, lactating women, or female participants who plan to become pregnant during the study period.
  12. Those who are known to be allergic to the test drug or any component of the test drug.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
176 participants (estimated)

Study arms

  • Experimental
    SHR0302 tablets in low dose group

    Drug: SHR0302 Tablets · Drug: SHR0302 Base Placebo Gel

  • Experimental
    SHR0302 tablets in high dose group

    Drug: SHR0302 Tablets · Drug: SHR0302 Base Placebo Gel

  • Experimental
    SHR0302 tablets + SHR0302 Base gel group

    Drug: SHR0302 Tablets · Drug: SHR0302 Base Gel

  • Placebo comparator
    SHR0302 placebo tablets + SHR0302 Base placebo gel group

    Drug: SHR0302 Placebo Tablets · Drug: SHR0302 Base Placebo Gel

Interventions

  • SHR0302 tablets.

  • SHR0302 Base gel.

  • DrugSHR0302 Placebo Tablets

    SHR0302 placebo tablets.

  • DrugSHR0302 Base Placebo Gel

    SHR0302 Base placebo gel.

06

What researchers measure

Primary outcomes

  1. The percentage change in the facial vitiligo area score index (F-VASI) from the baseline.

    Time frame: At Week 24.

Secondary outcomes

  1. The percentage change in F-VASI compared to the baseline.

    Except for Week 24.

    Time frame: Up to 48 weeks.

  2. The percentage change in the total body vitiligo area score index (T-VASI) compared to the baseline.

    Time frame: Up to 48 weeks.

  3. The proportion of subjects who achieved an improvement of at least 50%/75%/90% compared to the baseline on the F-VASI (F-VASI 50/75/90 response).

    Time frame: Up to 48 weeks.

  4. The proportion of subjects who achieved at least a 50%/75%/90% improvement in T-VASI compared to the baseline (T-VASI 50/75/90 response).

    Time frame: Up to 48 weeks.

  5. The absolute change in facial vitiligo area (F-BSA) compared to the baseline.

    Time frame: Up to 48 weeks.

  6. The percentage change in facial vitiligo area (F-BSA) compared to the baseline.

    Time frame: Up to 48 weeks.

  7. The percentage change the total body vitiligo area (T-BSA) compared to the baseline.

    Time frame: Up to 48 weeks.

  8. The absolute change the total body vitiligo area (T-BSA) compared to the baseline.

    Time frame: Up to 48 weeks.

  9. The proportion of subjects who achieved a significant improvement (4) on the Vitiligo Visual Scale (VNS).

    Time frame: Up to 48 weeks.

  10. The proportion of subjects who achieved a complete improvement (5) on the Vitiligo Visual Scale (VNS).

    Time frame: Up to 48 weeks.

  11. The absolute values of the changes in the vitiligo-specific quality of life scale (VitiQoL) compared to the baseline.

    Time frame: Up to 48 weeks.

  12. The percentages of the changes in the vitiligo-specific quality of life scale (VitiQoL) compared to the baseline.

    Time frame: Up to 48 weeks.

  13. The proportion of subjects who achieved the facial - vitiligo physician global assessment (F-PhGVA) of no depigmentation (0).

    Time frame: Up to 48 weeks.

  14. The proportion of subjects who achieved the facial - vitiligo physician global assessment (F-PhGVA) of almost no depigmentation (1).

    Time frame: Up to 48 weeks.

  15. The proportion of subjects who achieved the overall assessment of vitiligo by dermatologists (T-PhGVA) as no depigmentation (0).

    Time frame: Up to 48 weeks.

  16. The proportion of subjects who achieved the overall assessment of vitiligo by dermatologists (T-PhGVA) as almost no depigmentation (1).

    Time frame: Up to 48 weeks.

  17. The proportion of subjects who achieved a significant improvement (1) in the facial vitiligo condition as perceived by the overall impression (F-PaGIC-V).

    Time frame: Up to 48 weeks.

  18. The proportion of subjects who achieved a moderate improvement (2) in the facial vitiligo condition as perceived by the overall impression (F-PaGIC-V).

    Time frame: Up to 48 weeks.

  19. The proportion of subjects who achieved a significant improvement (1) in the overall impression (T-PaGIC-V) of generalized vitiligo.

    Time frame: Up to 48 weeks.

  20. The proportion of subjects who achieved a moderate improvement (2) in the overall impression (T-PaGIC-V) of generalized vitiligo.

    Time frame: Up to 48 weeks.

  21. The plasma concentration of SHR0302.

    Time frame: Week 12 and Week 24.

  22. The relative change in serum CXCL-9 level before administration compared to the baseline value.

    Time frame: At Week 4, 12, 24, 32, and 48.

  23. The relative change in serum CXCL-10 level before administration compared to the baseline value.

    Time frame: At Week 4, 12, 24, 32, and 48.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Mar 2027, 15 months after the start.

Of 44 phase 2 interventional studies under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 26. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Nov 26, 2025
StartActual
Dec 5, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Sep 2027
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07251595
Responsible party
Sponsor
First posted
Nov 26, 2025
Start date
Dec 5, 2025
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Feb 18, 2026

Study contacts

Hui Wang
Contact
hui.wang.hw119@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivarmacitinib

Start the discussion